0001104659-26-036878
SEC filingPrecipio delivered strong top-line growth and significantly narrowed losses in FY2025, progressing toward operational scale as it targets sustained profitability.
FY2025 revenue growth was driven by expanded diagnostic case volume, which the company notes enables its laboratory to leverage fixed expenses and deliver economies of scale. Higher case volumes also drove corresponding increases in variable cost of goods sold, including reagents, operating supplies, personnel costs, and pathologist interpretation costs, as outlined in management’s discussion. Even with these variable cost increases, gross profit growth outpaced revenue growth for the year, leading to a FY2025 gross margin of 44.5% as fixed cost leverage offset incremental variable expenses.
Operating and net losses narrowed significantly year-over-year in FY2025, reflecting the operational efficiency benefits of higher volume partially offsetting fixed and variable operating costs. Operating expenses for the period include personnel costs, professional fees, travel costs, facility costs, stock-based compensation, and depreciation and amortization, per MD&A disclosures. The company generated positive free cash flow for the full year, with operating cash flows supporting capital expenditures for laboratory assets as the company scales its operational footprint.
Management cautions that inflationary factors, including increases in cost of goods, labor, and other operating expenses, may adversely impact future operating results. The company notes it cannot guarantee it will be able to raise product prices or reduce operating expenses sufficiently to offset future inflationary pressures on gross margins. All future operating income is expected to be devoted to ongoing operations and growth initiatives, with a core strategic focus on expanding case volume to unlock additional scale benefits and progress toward sustained profitability.